CDRI开发口服活性骨折愈合药CDRI-1500，已获得印度和美国专利，并准备进行一期临床试验。 CDRI develops orally active fracture healing pill, CDRI-1500, receiving Indian and US patents and preparing for phase-1 clinical trials.

勒克瑙中央药物研究所（CDRI）开发了一种口服药 CDRI-1500，可以加速骨折的愈合。 Central Drug Research Institute (CDRI) in Lucknow has developed an oral pill, CDRI-1500, which could speed up the healing of fractures. 它是一流的口服活性骨折愈合合成分子，预计比现有的 BMP2 分子更安全、更经济、更快捷。 It's a first-in-class orally active fracture healing synthetic molecule, expected to be safer, more economical, and quicker than the existing BMP2 molecule. CDRI-1500已获得印度和美国专利，一期临床试验即将开始。 CDRI-1500 has received both Indian and US patents, with phase-1 clinical trials set to begin.